Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefpodoxime Proxetil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | PPARG | P37231 | 2/20 | 0.66 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.66 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.66 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.66 |
| ▸ | ALB | P02768 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | APEX1 | P27695 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefpodoxime Proxetil SCHEMBL4410291 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL29465200 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL6136644 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL8687125 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL27071 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL379709 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL7256264 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL7810065 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL22330291 | 1.00 | PTGS1 (1.00) | PTGS1ABCB11PDE4DNR1I2HTR2C | |
| Cefpodoxime Proxetil SCHEMBL5266189 | 0.99 | PTGS1 (0.99) | PTGS1ABCB11PDE4DNR1I2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269130-A1 | Antibiotice Susceptibility Profiling Methods | BECTON, DICKINSON AND COMPANY | 2011-11-03 | — | — | US | claimed |
| WO-2010048511-A1 | ANTIBIOTIC SUSCEPTIBILITY PROFILING METHODS | BECTON, DICKINSON AND COMPANY (US) | 2010-04-29 | — | — | WO | claimed |
| EP-1830849-B1 | FAST RELEASE DOSAGE FORMS FOR ANTIBIOTICS | GRUENENTHAL GMBH (DE) | 2009-11-11 | — | — | EP | claimed |
| EP-1071409-B1 | USE OF ORGANOPHOSPHORIC COMPOUNDS FOR THE THERAPEUTIC AND PREVENTATIVE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2003-10-15 | — | — | EP | claimed |
| US-11646117-B2 | Matrix factorization of antibiogram metadata | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| US-20200388384-A1 | MATRIX FACTORIZATION OF ANTIBIOGRAM METADATA | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-10675278-B2 | Crush resistant delayed-release dosage forms | Grünenthal GmbH (DE) | 2020-06-09 | — | — | US | disclosed |
| CN-110496101-A | A kind of stable vitamin K2Submicron Emulsion and preparation method thereof | SUNGEN BIOSCIENCE CO LTD | 2019-11-26 | — | — | CN | disclosed |
| US-20180369235-A1 | CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS | Grünenthal GmbH (DE) | 2018-12-27 | — | — | US | disclosed |
| US-20170312271-A1 | CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS | Grünenthal GmbH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9750701-B2 | Pharmaceutical dosage form | Grünenthal GmbH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-9604018-B2 | Aerosol therapy device | PARI PHARMA GMBH (DE) | 2017-03-28 | — | — | US | disclosed |
| EP-1365764-A1 | ORAL PHARMACEUTICAL COMPOSITION OF CEFPODOXIME PROXETIL | RANBAXY LABORATORIES, LTD. (IN) | 2003-12-03 | — | — | EP | disclosed |
| US-6638957-B1 | Inhibition of 1-deoxy-D-xylulose-5-phosphate metabolic pathway | JOMAA PHARMAKA GMBH (DE) | 2003-10-28 | — | — | US | disclosed |
| US-20030144249-A1 | Use of organophosphorous compounds for producing a medicament for treating infections | JOMAA PHARMAKA GMBH (DE) | 2003-07-31 | — | — | US | disclosed |
| US-6534489-B1 | Organophosphorus compounds and the use thereof | JOMAA PHARMAKA GMBH (DE) | 2003-03-18 | — | — | US | disclosed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | disclosed |
| WO-2002067943-A1 | ORAL PHARMACEUTICAL COMPOSITION OF CEFPODOXIME PROXETIL | RANBAXY LABORATORIES LIMITED (IN) | 2002-09-06 | — | — | WO | disclosed |
| EP-0548790-B1 | (1'S)-Hydroxyalkyloxapenem-3-carboxylic acids and their use as beta-lactamase inhibitors | LILLY CO ELI (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0548790-A1 | (1'S)-Hydroxyalkyloxapenem-3-carboxylic acids and their use as beta-lactamase inhibitors | ELI LILLY AND COMPANY (US) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | HRH2, ASPH, NQO2 | PTGS1 1766/4885ABCB11 234/4885PDE4D 4240/4885 |
| US-20030144249-A1 | Use of organophosphorous compounds for producing a medicament for treating infections | PHPT1, PPM1D, BPNT1 | PTGS1 2475/4885ABCB11 1550/4885PDE4D 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.